Puma Biotechnology Inc PBYI
News
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)